Bortezomib Hospira 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0024 
A.5.a - Administrative change - Change in the name 
06/10/2023 
and/or address of a manufacturer/importer 
responsible for batch release 
amended 
on 
Annex II and 
PL 
IA/0022 
A.6 - Administrative change - Change in ATC 
28/02/2022 
03/02/2023 
SmPC and PL 
Code/ATC Vet Code 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
R/0020 
Renewal of the marketing authorisation. 
25/02/2021 
28/04/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Bortezomib Hospira in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IA/0021 
A.7 - Administrative change - Deletion of 
02/03/2021 
24/02/2022 
Annex II and 
manufacturing sites 
PL 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
10/12/2020 
11/02/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02004 
bortezomib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/424/202004. 
IB/0018/G 
This was an application for a group of variations. 
18/09/2020 
11/02/2021 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0015/G 
This was an application for a group of variations. 
28/02/2020 
n/a 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
Page 3/7 
 
 
 
 
 
 
 
 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
N/0016 
Minor change in labelling or package leaflet not 
02/12/2019 
11/02/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
01904 
bortezomib 
N/0013 
Minor change in labelling or package leaflet not 
12/04/2019 
11/02/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
13/12/2018 
14/02/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01804 
bortezomib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/424/201804. 
IB/0012/G 
This was an application for a group of variations. 
18/12/2018 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
an obsolete parameter) 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.d.1.z - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Other 
variation 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
II/0008 
B.II.e.5.c - Change in pack size of the finished 
08/11/2018 
14/02/2019 
SmPC, Annex 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
II, Labelling 
and PL 
T/0010 
Transfer of Marketing Authorisation 
17/07/2018 
08/08/2018 
SmPC, 
Labelling and 
PL 
IAIN/0011 
B.II.b.2.c.1 - Change to importer, batch release 
30/07/2018 
14/02/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
30/11/2017 
n/a 
PRAC Recommendation - maintenance 
01704 
bortezomib 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0007 
Minor change in labelling or package leaflet not 
13/11/2017 
18/01/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0006/G 
This was an application for a group of variations. 
26/10/2017 
18/01/2018 
SmPC, Annex 
The Product Information has been updated with the 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
II, Labelling 
inclusion of two new presentations of 2.5 mg and 3.0 mg of 
and PL 
bortezomib powder per vial. The volume of reconstitution of 
the powder for the new presentations is such that the 
bortezomib concentration in the final solution for injection 
and hence the posology, computed based on body surface 
area is unaffected. 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/07/2017 
18/01/2018 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IA/0003 
B.II.e.6.b - Change in any part of the (primary) 
13/06/2017 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
N/0002 
Minor change in labelling or package leaflet not 
14/02/2017 
18/01/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
27/01/2017 
18/01/2018 
SmPC 
storage conditions of the finished product - Other 
variation 
Page 7/7 
 
 
 
 
 
 
 
 
 
